Clovis planning $200 million note deal

Clovis Oncology Inc. (NASDAQ:CLVS) proposed late Tuesday to raise $200 million through the sale of senior convertible notes due 2021 in a private placement to institutional investors. Clovis' rucaparib ( CO-338) is in the Phase III ARIEL3 trial to treat platinum-sensitive, relapsed ovarian, fallopian tube or primary peritoneal cancer. Clovis has exclusive, worldwide rights to the oral inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1) and PARP-2 from Pfizer Inc. (NYSE:PFE). ...